Brings Advantages of MRI-Guided Radiation Therapy to Treatment of Lung, Liver and Pancreatic Cancer Patients
The MRIdian System combines MR imaging with radiation delivery so clinicians can visualize soft tissue and adjust their dosing — all in real-time, on live anatomy. With MRIdian this is done without exposing the patient to the additional ionizing radiation that is common with other imaging modalities.
“We’re pleased to have commenced patient treatments with our MRIdian System and are already seeing firsthand the benefits of combining MRI with radiation delivery and the value of adapting our plan during treatment to account for motion and changes in the tumor and nearby anatomy,” said Jun Itami, M.D., Ph.D., chair of the Department of Radiation Oncology, NCC. “MRIdian will allow us to expand the number and types of cancer patients we treat, including some patients who may have been considered untreatable previously with conventional radiation therapy.”
The National Cancer Center Japan has been providing patient care for more than 50 years. The NCC is at the forefront of research in cancer treatment and plays a central role in training doctors, nurses and other medical professionals to specialize in cancer medicine.
“It’s exciting to have the first MRIdian treatments in Japan underway at the NCC,” said Chris A. Raanes, president and chief executive officer of ViewRay. “MRIdian offers significant advantages in its real-time soft-tissue tracking and on-table adaptive delivery, and we’re pleased that patients in Japan are now experiencing the benefits of this important advance in cancer care.”
ViewRay received Shonin approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) in August 2016 to market the Cobalt-based MRIdian System within Japan. ViewRay is represented in Japan by ITOCHU Corporation, one of the three largest general trading companies in Japan. ITOCHU has been focusing on the healthcare business to promote important medical innovations in Japan for approximately 40 years.
ViewRay and MRIdian are registered trademarks of ViewRay, Inc.
Forward Looking Statements:
This press release contains forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to the benefits of the MRIdian System for physicians and patients in Japan and the first patient treatments by the NCC. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue ViewRay’s business and product development plans, the inherent uncertainties associated with developing new products or technologies, competition in the industry in which ViewRay operates and overall market conditions. These forward-looking statements are made as of the date of this press release, and ViewRay assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents ViewRay files with the SEC available at www.sec.gov.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/national-cancer-center-japan-treats-first-patients-using-viewray-mridian-system-300479376.html